Paradigm in the news

 
Paradigm Careers
11.05.15

Paradigm Leadership Plays Significant Role on Study Published in NEJM Defining the Genetic Basis of Papillary Renal-Cell Carcinoma

Paradigm’s Executive Team has provided key leadership and expertise in a study to define genomic changes in papillary renal-cell carcinoma that has provided the most comprehensive and integrated view of gene changes for kidney cancer to date. Conventional evaluation characterizes papillary renal-cell carcinoma as a heterogeneous disease constituting various types of renal cancer; however, precious […]

Read more
 
 
Paradigm Careers
09.24.15

Genomic Profiling Study Brings Personalized Medicine to Metastatic Bladder Cancer Patients

Bethesda, MD – September 24, 2015 — The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center. This prospective study is the first project of the Bladder Cancer Genomics Consortium (BCGC), […]

Read more
 
 
Paradigm Careers
08.19.15

Paradigm Announces Molecular Profiling Collaboration for Study of Altiratinib In Genomically Defined Cancer Patients

Collaboration designed to assess key molecular targets associated for phase I clinical trial [ANN ARBOR, MI and PHOENIX, AZ, August 19, 2015] Paradigm today announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, […]

Read more
 
 
Paradigm Careers
08.07.15

Paradigm Expands Access to PCDX Personalized Medicine Service by Signing Contract with Three Rivers Provider Network

Paradigm Cancer Diagnostic (PCDxTM) test now accessible to an additional 15 Million covered lives in US [Ann Arbor, MI and Phoenix, AZ, August 7, 2015]– Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, has signed an agreement with health insurer Three Rivers Provider Network, Inc., […]

Read more
 
 
Paradigm Careers
08.06.15

Paradigm and TME Research To Launch Precision Medicine Breast Cancer Registry

Registry is designed to determine clinical impact of molecular profiling on breast cancer patients being treated in the neoadjuvant setting [ANN ARBOR, MI and Allentown, PA, August 06, 2015]– Paradigm and TME Research today announced the launch of a precision medicine breast cancer registry. The Paradigm Neoadjuvant Breast Registry will use Paradigm’s PCDx next generation […]

Read more
 
 
Paradigm Careers
07.15.15

Paradigm Signs Contract With Stratose for Personalized Medicine Service

Will Help Provide Paradigm Cancer Diagnostic (PCDx™) to Oncologists and Large Member Base ANN ARBOR, Mich. and PHOENIX, July 15, 2015 /PRNewswire-USNewswire/ — Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, today announced that it has entered into a contractual agreement with Stratose for coverage […]

Read more
 
 
Paradigm Careers
04.28.15

Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study

Analysis of next-generation sequencing (NGS)-based platforms suggests potential benefits of novel NGS platform for cancer patients. [PHOENIX, AZ and ANN ARBOR, April 28, 2015] —Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine’s FoundationOne test across a number of key clinical […]

Read more
 
 
Paradigm Careers
04.20.15

Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service

Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network [SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015]– Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2’s affiliated oncology provider networks. PCDx is a Next-Generation […]

Read more
 
 
Paradigm Careers
02.03.15

Paradigm Announces Enhancement to PCDx Cancer Testing Service

Addition of Protein Biomarkers, Including Key Immune Targets PD-L1 and PD1, Further Augments Tests Ability to Personalize Cancer Therapy [PHOENIX, AZ and ANN ARBOR, MI February 3, 2015]– Paradigm today announced an expansion to their Next Generation Paradigm Cancer Diagnostic (PCDx) service with the addition of key protein biomarkers analyzed by immunohistochemistry (IHC). This enhancement […]

Read more
 
 
Paradigm Careers
08.20.14

Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc.

Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies. Ann Arbor, MI and Phoenix AZ, August 20, 2014 Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, today announced a collaboration with TESARO, Inc. Paradigm […]

Read more
 

Start getting better results, faster.

Order PCDx